Groundbreaking Technology
Solid tumors have been a challenging obstacle for all cancer therapies, including immunotherapies, reporting high failure rates. For six decades researchers have taken steps towards a cure, with remarkable progress in liquid tumors, but few inroads into solid tumors representing 90% of all cancers .
Our allogeneic technology represents a transformative approach that captures the true power of both innate and adaptive immunity to effectively treat even refractory solid tumors.